Adding Pirtobrutinib to Venetoclax-Rituximab Shows Significant Improvement in PFS Among Patients with Previously Treated CLL By Ogkologos - August 6, 2026 56 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the BRUIN CLL-322 study Source RELATED ARTICLESMORE FROM AUTHOR New Translations of the ESMO Patient Guides Available in Estonian Trend in Survival Benefit with a Combination of Spartalizumab Plus Dabrafenib and Trametinib Over Targeted Therapy Alone for BRAF V600-mutated Metastatic Melanoma FDA Approves Pembrolizumab or Pembrolizumab and Berahyaluronidase alfa-pmph Each with Enfortumab Vedotin-ejfv for Muscle Invasive Bladder Cancer MOST POPULAR AI Model Identifies How Every Country Can Improve Its Cancer Outcomes January 14, 2026 Foodie Fridays-Gazpacho: A Favorite Summer Soup August 6, 2021 New Study Says At-Home Cancer Care May Lead to Fewer Hospitalizations... May 20, 2021 Help Desk for Oncologists Treating People with a Rare Leukemia Pays... February 2, 2023 Load more HOT NEWS Adding Pembrolizumab to Chemotherapy Results in Improved PFS and OS in... How My Stage 4 Esophageal Cancer Diagnosis Led Me to a... Taking Control – Risks vs. Benefits Researchers Discover Way to Help Immunotherapy Better Target Solid Tumors Like...
